Peptides for Perimenopause: Hormones, Weight & Wellbeing

Perimenopause is the transitional phase before menopause, typically beginning in a woman's early-to-mid 40s (though it can start in the late 30s). Unlike menopause — which is a single point in time (12 months after the last period) — perimenopause is a process that can last 4-10 years.

During this phase, oestrogen and progesterone levels fluctuate unpredictably rather than declining steadily. This hormonal volatility drives the characteristic symptoms:

• •Weight gain — particularly around the midsection (visceral fat accumulation)
• •Hot flushes and night sweats — vasomotor symptoms affecting up to 80% of women
• •Sleep disruption — difficulty falling or staying asleep
• •Mood changes — anxiety, irritability, low mood
• •Joint and muscle pain — oestrogen decline affects connective tissue
• •Cognitive changes — brain fog, concentration difficulties
• •Skin changes — reduced collagen, dryness, loss of elasticity

The UK average age of menopause is 51, meaning perimenopause often begins around 45-47. An estimated 13 million women in the UK are currently perimenopausal or menopausal.

Before discussing peptides, it's essential to acknowledge that hormone replacement therapy (HRT) is the evidence-based first-line treatment for perimenopause symptoms.

NICE guideline NG23 recommends: - HRT for vasomotor symptoms (hot flushes, night sweats) - HRT for mood symptoms related to menopause - HRT can be started during perimenopause — you do not need to wait for periods to stop - Body-identical hormones (oestradiol patches/gel + micronised progesterone) are preferred

NHS access: Any GP can prescribe HRT. Specialist menopause clinics exist for complex cases. The prepayment certificate (PPC) at £31.25/quarter covers unlimited prescriptions.

Peptides are NOT a replacement for HRT. They may complement conventional treatment for specific symptoms, but the evidence base is much weaker than for HRT. Any perimenopausal woman should discuss HRT with her GP before exploring peptides.

Several peptide categories may be relevant to specific perimenopausal concerns:

Weight management — GLP-1 agonists (semaglutide, tirzepatide) Perimenopausal weight gain is driven by hormonal shifts (increased visceral fat deposition, insulin resistance, reduced metabolic rate). GLP-1 agonists are the most effective pharmaceutical weight loss interventions and are available on NHS prescription for eligible patients.

Kisspeptin — reproductive hormone regulation Kisspeptin is a key regulator of the hypothalamic-pituitary-gonadal axis. Research at Imperial College London has explored kisspeptin's role in reproductive hormone signalling. During perimenopause, kisspeptin neuron sensitivity changes, contributing to vasomotor symptoms. This is an active research area but not yet therapeutic.

DSIP — sleep support Delta sleep-inducing peptide is researched for sleep quality. Perimenopausal sleep disruption — often driven by night sweats and hormonal fluctuations — is a major quality-of-life issue. DSIP remains a research compound with limited human data.

BPC-157 — joint and connective tissue Oestrogen decline affects joint cartilage, tendons, and ligaments. Many perimenopausal women experience new or worsening joint pain. BPC-157 is researched for its effects on connective tissue repair, though human evidence is absent.

Collagen peptides — skin and joints Oral collagen peptides (hydrolysed collagen) have the most evidence of any peptide supplement for perimenopausal women. Clinical trials show improvements in skin elasticity, hydration, and joint comfort. These are available as food supplements in the UK without prescription.

Available on NHS: - HRT (first-line for perimenopausal symptoms) - GLP-1 agonists (Wegovy, Mounjaro — for weight management with BMI criteria) - CBT for menopause symptoms (NICE-recommended)

Available as supplements (no prescription needed): - Collagen peptides (food supplement — Boots, Holland & Barrett, online) - These are the only peptides with reasonable evidence for perimenopause that don't require a prescription

Available privately (prescription required): - GLP-1 agonists through private clinics if NHS criteria not met - Some private clinics offer broader peptide therapy (regulatory grey area)

Research only (not available for clinical use): - Kisspeptin, DSIP, BPC-157 — unapproved research compounds

Priority order for perimenopausal women: 1. Discuss HRT with your GP (evidence-based, NHS-available) 2. Address lifestyle factors (exercise, diet, sleep hygiene, stress) 3. Consider collagen peptides as a supplement (low-risk, modest evidence) 4. Explore GLP-1 agonists if weight management is a primary concern 5. Research peptides only under medical supervision and with realistic expectations

If you're perimenopausal and interested in peptides:

1. Start with your GP. Discuss your symptoms. Request blood tests (FSH, oestradiol — though these fluctuate in perimenopause and are not always diagnostic). Discuss HRT options.

2. Track your symptoms. Apps like Balance (endorsed by Dr Louise Newson) help track symptoms and provide evidence to take to your GP.

3. Prioritise evidence-based interventions. HRT, exercise (particularly resistance training and weight-bearing exercise), adequate protein, calcium, and vitamin D.

4. If considering GLP-1 agonists for weight, check NHS eligibility criteria (BMI ≥30, or ≥27 with comorbidities). Private options exist if NHS criteria are not met.

5. Be cautious with research peptides. Most perimenopausal peptide claims come from extrapolating animal or in-vitro data. The evidence for HRT is incomparably stronger.

6. Collagen peptides are reasonable. 5-10g daily of hydrolysed collagen peptides has clinical trial support for skin and joint benefits. Look for brands with published clinical data.

*This guide is for educational purposes only. Perimenopause is a medical transition that benefits from professional guidance. Consult your GP or a menopause specialist for personalised advice.*